Encepur Tick-Borne Encephalitis Vaccine Clinical Trials, Dosage, Safety
Encepur® is a whole virus vaccine containing an inactivated and purified Tick-Borne Encephalitis (TBE) virus/strain prevalent in Central, Eastern, and Northern Europe. The World Health Organization (WHO) recommends vaccination for all age groups, including children, in areas where the disease is highly endemic.
This vaccine is based on the European subtype virus strain K23, isolated in Karlsruhe, Germany, and licensed in 1991 as Encepur by Chiron Behring. Similar to FSME-IMMUN, the virus is grown on primary chick embryo cells, inactivated with formaldehyde, and contains 1.5 mcg of antigen. The genomic sequence of the K23 vaccine in the Encepur formulation contains mutations relative to the original sequence, but the clinical impact of these changes is unclear.
Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. In late 2019, Bavarian Nordic acquired Encepur from GSK, and while manufacturing will transition over the next five years, sales and marketing responsibilities started in 2020.
Encepur Vaccine Indication
Encepur is indicated for active immunization of high-risk populations against TBE. The WHO recommends considering the Tick-Borne encephalitis vaccine for travelers at higher risk of the disease, as vaccination offers the most effective protection, and recommends vaccinating all age groups, including children, in areas where the disease is highly endemic. As of Movember 2025, Encepur's revenue grew 15% in the first nine months compared to the prior year, driven by strong market growth and increased market share.
Encepur Vaccine Dosage
Encepur is administered as an intramuscular injection. Its unique dosing flexibility is supported by proven efficacy and long-term persistence data. ENCEPUR's rapid schedule: immunisation completed in just 21 days. A pediatric version with half the adult dose has been available since 1994. For children aged >1 year (ENCEPUR CHILDREN, 0.25 mL) and for Adults and children aged > 12 years (ENCEPUR ADULTS, 0.5 mL).
Encepur Vaccine Booster
ENCEPUR booster protects those at ongoing risk of TBE and is recommended every 5 years for those aged 1-49 and every 3 years for those aged>49.
Encepur Vaccine Availability 2026
As of 2026, Encepur is marketed only in European countries, with Germany as the largest market.
Encepur Vaccine News
February 12, 2026 - The company announced strong demand for its TBE vaccine with 20% annual revenue growth.
May 9, 2025 - Bavarian Nordic A/S reported its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million.
October 21, 2019 - Bavarian Nordic announced that it has entered an agreement with GlaxoSmithKline to acquire the manufacturing and global rights to Encepur®.
Encepur Vaccine Clinical Trials
Clinical Trial NCT03294135: This Study aims to investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine.